Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers
Yap, T A Krebs, Matthew G Soria, JC Ross, G Stephens, C Khan, M Berges, A Im, S A Castanon-Alvarez, E Postel-Vinay, S
Yap, T A
Krebs, Matthew G
Soria, JC
Ross, G
Stephens, C
Khan, M
Berges, A
Im, S A
Castanon-Alvarez, E
Postel-Vinay, S
Citations
Altmetric:
Abstract
Description
Date
2016
Publisher
Collections
Keywords
Type
Article
Citation
Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. 2016, 69:S2 Eur J Cancer